Not enough data
Hogan Lovells' coverage indicates a strong focus on legal and regulatory developments across various industries, particularly in areas such as privacy regulations, financial regulations, employment law, and antitrust. Given this emphasis, they are likely to be interested in experts who can provide insights into the evolving legal and compliance landscape within these specific sectors.
The firm also covers government announcements and industry-specific topics extensively. As such, pitches offering expert commentary or analysis related to new laws or regulatory changes at both national and international levels would be highly relevant.
Considering their wide-ranging coverage of legal themes with no specific geographic focus mentioned, Hogan Lovells could benefit from receiving pitches that offer comprehensive expertise addressing global legal trends impacting businesses across different sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Hogan Lovells, Stephanie Gold, William Ferreira, Stewart Forbes, Ambia Harper
On May 29, 2026, the Office of Management and Budget (“OMB”) published a proposed rule in the Federal Register that would comprehensively revise 2 ...
By: Gary Veron
In June 2026, FDA's Center for Drug Evaluation and Research issued draft guidance addressing common questions about Forms FDA 3542a and FDA 3542—the
By: Mauricio Llamas, Hogan Lovells, Sofía De Llano, Mauricio Villegas
Key takeaways In December 2025, the National Waters Law was amended. Among the relevant changes, the amendment modified the regime governing the...
By: Zhen Feng, Grace Guo, Stefaan Meuwissen
China has issued its most significant update to administrative trade secret protection in nearly thirty years.
By: Julia Mischie, Hein Van
The revision of the EU pharmaceutical legislation is close to final, with adoption of the revised legal framework expected by fall of 2026.
By: Samantha Van Dijk, Hein Van
The revision of the pharmaceutical legislation in the European Union (EU) is close to final, and the new legal framework, the "EU General Pharmaceutical Law," is expected to be adopted by autumn 2026.
Welcome to our latest update, in which we cover: Auto-enrolment: alternative quality requirements for defined benefit (DB), hybrid and collective d...
By: Ingrid Stables, Stella Bliss, Lucy Redman
We now have more clarity on how the new contractual controls regime will operate in England and Wales.
By: Stefano Maccauro, Chiara Vallone
On 10 June 2026, by means of Notice C/2026/3084 , the European Commission published in the Official Journal of the European Union a guidance document
By: Hogan Lovells, Peter Watts, Alice Wallace-Wright, Caitlin Weeks, Louise Crawford
In our recent article "Emerging tech" and why it is different, we explored what makes emerging tech deals different from ‘traditional’ M&A deals. I...
